Home » Stocks » Mirati Therapeutics

Mirati Therapeutics, Inc. (MRTX)

Stock Price: $131.59 USD 5.78 (4.59%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 5.86B
Revenue (ttm) 1.78M
Net Income (ttm) -296.16M
Shares Out 44.54M
EPS (ttm) -7.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $131.59
Previous Close $125.81
Change ($) 5.78
Change (%) 4.59%
Day's Open 126.67
Day's Range 125.92 - 132.98
Day's Volume 271,317
52-Week Range 66.01 - 137.29

More Stats

Market Cap 5.86B
Enterprise Value 5.22B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 44.54M
Float 30.15M
EPS (basic) -7.15
EPS (diluted) -7.16
FCF / Share -4.47
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.99M
Short Ratio 15.90
Short % of Float 12.99%
Beta 1.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3,290.91
PB Ratio 9.63
Revenue 1.78M
Operating Income -306.06M
Net Income -296.16M
Free Cash Flow -196.03M
Net Cash 645.71M
Net Cash / Share 14.50
Gross Margin 187.25%
Operating Margin -17,184.50%
Profit Margin -16,629.00%
FCF Margin -11,006.79%
ROA -32.83%
ROE -54.97%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (14)

Buy 13
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(7.62% upside)
Current: $131.59
Target: 141.62
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-74.2%--------
Gross Profit3.3412.93------3.14
Operating Income-222-103-71.54-83.78-64.71-39.10-32.00-20.50-10.09
Net Income-213-98.42-70.43-83.12-64.54-43.70-52.86-20.29-9.78
Shares Outstanding37.4730.9025.2919.7916.9013.4811.066.764.94
Earnings Per Share-5.69-3.19-2.78-4.20-3.82-3.24-4.78-3.00-1.98
Operating Cash Flow-148-70.10-64.71-68.02-50.71-32.75-29.46-16.65-11.64
Capital Expenditures-1.55-0.12-0.08-0.20-0.33-0.39-0.20-0.23-0.03
Free Cash Flow-149-70.22-64.79-68.21-51.04-33.13-29.66-16.88-11.68
Cash & Equivalents41522315156.7312229.3062.0736.9828.74
Net Cash / Debt41522315156.7312229.3062.0736.9828.74
Book Value38220214348.3111828.0625.8934.4227.31
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mirati Therapeutics, Inc.
Country United States
Employees 111
CEO Charles M. Baum

Stock Information

Ticker Symbol MRTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MRTX
IPO Date June 29, 2004


Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.